Adverse events: malignancy · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether immunosuppressive treatment changes adverse events: malignancy at final compared with placebo/no treatment/non‐immunosuppressive supportive treatment (very low certainty).
1 finding from 1 review
Adverse events: infection at 3 years · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether immunosuppressive treatment changes adverse events: infection at 3 years compared with placebo/no treatment/non‐immunosuppressive supportive treatment (very low certainty).
1 finding from 1 review
Adverse events ‐ temporary or permanent discontinuation/hospitalisation at final · primary membranous nephropathy in adults with nephrotic syndrome
Immunosuppressive treatment probably leads to higher adverse events: temporary/permanent discontinuation or… compared with placebo/no treatment/non‐immunosuppressive supportive treatment (moderate certainty).
1 finding from 1 review
Adverse effects of antibiotics (skin rash) · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: skin rash compared with cyclosporin/prednisolone (very low certainty).
1 finding from 1 review
Adverse events: hypotension · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: hypotension compared with cyclosporin/prednisolone (very low certainty).
1 finding from 1 review
Adverse events: mild dyspnoea · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: mild dyspnoea compared with cyclosporin/prednisolone (very low certainty).
1 finding from 1 review
Adverse events: bronchospasm/treatment discontinued · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: bronchospasm/treatment discontinued compared with cyclosporin/prednisolone (very low certainty).
1 finding from 1 review
Adverse events · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adult patients after liver transplantation.
It is very uncertain whether synbiotics changes adverse events compared with prebiotics (very low certainty).
1 finding from 1 review
All adverse events · children with previous UTI and most do not have a renal tract abnormality such as VUR
Antibiotic treatment showed no clear difference in all adverse events compared with placebo or no treatment (low certainty).
1 finding from 1 review
Serious adverse events · adult patients after liver transplantation.
It is very uncertain whether synbiotics changes serious adverse events compared with prebiotics (very low certainty).
1 finding from 1 review
Serious adverse events ( · preventing the progression of CKD
Metformin showed no clear difference in serious adverse events ( compared with active control (moderate certainty).
1 finding from 1 review
Serious adverse events ( · preventing the progression of CKD
Metformin showed no clear difference in serious adverse events ( compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events: hypertension · anaemia in predialysis patients
Epoetin alfa every four weeks showed no clear difference in adverse events: hypertension compared with with every two weeks (moderate certainty).
1 finding from 1 review
Adverse events: hypertension · anaemia in predialysis patients
Epoetin theta showed no clear difference in adverse events: hypertension compared with epoetin beta (moderate certainty).
1 finding from 1 review
Adverse events: hypertension · anaemia in predialysis patients
Epoetin alpha every 2 weeks showed no clear difference in adverse events: hypertension compared with to weekly (moderate certainty).
1 finding from 1 review
Gastrointestinal adverse events · preventing UTI
Any cranberry product showed no clear difference in gastrointestinal adverse events compared with placebo or control (moderate certainty).
1 finding from 1 review
Adverse events: RBC transfusions · anaemia in predialysis patients
Epoetin alfa every four weeks showed no clear difference in adverse events: RBC transfusions compared with with every two weeks (low certainty).
1 finding from 1 review
Adverse events: RBC transfusions · anaemia in predialysis patients
Epoetin theta showed no clear difference in adverse events: RBC transfusions compared with epoetin beta (low certainty).
1 finding from 1 review
Adverse events: RBC transfusions · anaemia in predialysis patients
Epoetin alpha every 2 weeks showed no clear difference in adverse events: RBC transfusions compared with to weekly (low certainty).
1 finding from 1 review